- Home
- PKG vs MRNA Comparison
PKG vs MRNA Comparison
Compare PKG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PKG | MRNA |
|---|---|---|
| Founded | 1867 | 2010 |
| Country | United States | United States |
| Employees | 13600 | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 21.6B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PKG | MRNA |
|---|---|---|
| Price | $241.71 | $67.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 12 |
| Target Price | ★ $232.38 | $34.27 |
| AVG Volume (30 Days) | 592.1K | ★ 6.9M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.91 | N/A |
| Revenue | $8,989,300,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $13.32 | $9.36 |
| Revenue Next Year | $4.61 | $15.43 |
| P/E Ratio | $126.15 | ★ N/A |
| Revenue Growth | ★ 7.23 | 4.29 |
| 52 Week Low | $187.42 | $22.28 |
| 52 Week High | $249.51 | $67.74 |
Technical Indicators
Market Signals| Indicator | PKG | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.41 | 69.22 |
| Support Level | $202.02 | $45.69 |
| Resistance Level | $249.51 | N/A |
| Average True Range (ATR) | 6.20 | 4.81 |
| MACD | 1.35 | 1.33 |
| Stochastic Oscillator | 87.96 | 86.50 |
Price Performance
Historical ComparisonAbout PKG Packaging Corporation of America
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.